Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial.
Smilowitz NR, Hade EM, Kornblith LZ, Castellucci LA, Cushman M, Farkouh M, Gong MN, Heath A, Hunt BJ, Kim KS, Kindzelski A, Lawler P, Leaf DE, Goligher E, Leifer ES, McVerry BJ, Reynolds HR, Zarychanski R, Hochman JS, Neal MD, Berger JS.
Smilowitz NR, et al.
Res Pract Thromb Haemost. 2023 Aug 9;7(6):102167. doi: 10.1016/j.rpth.2023.102167. eCollection 2023 Aug.
Res Pract Thromb Haemost. 2023.
PMID: 37727846
Free PMC article.